Cargando…
Post-Menopausal Quality of Life Claims: Overlooking the Requirements of Normal Science and Fundamental Measurement in ICER’S Cost-Effectiveness Assessment of Fezolinetant for Moderate to Severe Vasomotor Symptoms
One of the signal failures in health technology assessment is the absence of consideration given, not only to the standards of normal science, but to those of fundamental measurement. A recent evidence report by the Institute for Clinical and Economic Review (ICER) is emblematic of this failure. Bas...
Autor principal: | Langley, Paul C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
University of Minnesota Libraries Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10686681/ https://www.ncbi.nlm.nih.gov/pubmed/38035319 http://dx.doi.org/10.24926/iip.v14i1.5118 |
Ejemplares similares
-
Neurokinin Receptor Antagonist, Fezolinetant, for Treatment of Menopausal Vasomotor Symptoms
por: Pinkerton, JoAnn V, et al.
Publicado: (2023) -
Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT
por: Johnson, Kimball A, et al.
Publicado: (2023) -
Safety of Fezolinetant for Vasomotor Symptoms Associated With Menopause: A Randomized Controlled Trial
por: Neal-Perry, Genevieve, et al.
Publicado: (2023) -
“Veozah (Fezolinetant): A Promising Non‐Hormonal Treatment for Vasomotor Symptoms in Menopause”
por: Shaukat, Ayesha, et al.
Publicado: (2023) -
OR06-5 Fezolinetant for Treatment of Moderate-to-severe Vasomotor Symptoms Associated with Menopause: Results from a 52-week Study (Skylight 2)
por: English, Marci, et al.
Publicado: (2022)